몰리노 침바롱고 cl KR20180059544A - Combination therapy with … The present invention relates to a combination of a glutaminase inhibitor and an immuno-oncologic therapeutic agent such as arginase, CTLA-4, indoleamine 2,3-dioxigenin and / or an inhibitor of PD-1 / PD- Myeloproliferative disorders, or immunological or neurological disorders.